Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
March 04 2019 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
Richard Murray, Ph.D., chief executive officer and president of
Jounce Therapeutics, will present at the Cowen and Company 39th
Annual Health Care Conference on Monday, March 11, 2019 at 11:20 AM
ET in Boston, MA.
A live webcast of the presentation will be available by visiting
"Events & Presentations" in the Investors and Media section of
the company's website at www.jouncetx.com. A replay of the webcast
will be archived for 30 days following the presentation.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within the
human tumor microenvironment to prioritize targets, and then
identifies related biomarkers designed to match the right
immunotherapy to the right patient. Jounce has three
development-stage programs: its two clinical product candidates,
JTX-2011, a monoclonal antibody that binds to and
activates ICOS, and JTX-4014, a monoclonal antibody that binds
to PD-1 and for potential use in combination with Jounce’s pipeline
of future product candidates, and JTX-8064, a monoclonal antibody
that binds to Leukocyte Immunoglobulin Like Receptor B2 (LILRB2)
that is currently in the IND-enabling phase. For more information,
please visit www.jouncetx.com.
Investor Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Media Contact:Gina NugentThe Yates Network(617)
460-3579gina@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024